Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Helsinn Group and BridgeBio Pharma Inc (NASDAQ:BBIO) have updated their existing strategic collaboration to develop, manufacture, and commercialize infigratinib for oncology indications.
- Under the amended and restated agreement terms, Helsinn will gain an exclusive license to commercialize infigratinib in the U.S.
- Helsinn will be responsible for developing, manufacturing, and commercializing infigratinib in oncology indications except for achondroplasia or any other skeletal dysplasias except in mainland China, Hong Kong, and Macau.
- Also See: Why BridgeBio Pharma Shares Are Plummeting Today?
- BridgeBio will be eligible to receive regulatory and commercial milestone payments and tiered royalties on adjusted net sales from Helsinn.
- BridgeBio will retain all rights to develop, manufacture and commercialize infigratinib in skeletal dysplasia, including achondroplasia.
- Price Action: BBIO shares are down 1.21% at $8.16 during the market session on the last check Thursday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!